__NUXT_JSONP__("/drugs/Topotecan", (function(a,b,c){return {data:[{drug:{slug:b,emaEpar:[{activeSubstance:a,conditionIndication:"Topotecan monotherapy is indicated for the treatment of patients with relapsed small-cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination.",inn:a,marketingAuthorisationDate:"2010-06-09 00:00:00",marketingAuthorisationHolder:"Pfizer Europe MA EEIG",medicineName:"Topotecan Hospira",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Ftopotecan-hospira"},{activeSubstance:a,conditionIndication:"Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.",inn:a,marketingAuthorisationDate:"1996-11-12 01:00:00",marketingAuthorisationHolder:"Novartis Europharm Limited",medicineName:"Hycamtin",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fhycamtin"},{activeSubstance:a,conditionIndication:"Topotecan monotherapy is indicated for the treatment of:patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapypatients with relapsed small cell lung cancer (SCLC) for whom re-treatment with thefirst-line regimen is not considered appropriate.Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.",inn:a,marketingAuthorisationDate:"2011-01-06 01:00:00",marketingAuthorisationHolder:"Actavis Group PTC ehf",medicineName:"Potactasol",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fpotactasol"}],fdaDrugLabel:[{brand:b,indication:"1 INDICATIONS AND USAGE Topotecan Injection is indicated for the treatment of: small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies ( 14 ) ] . Topotecan Injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and\u002For radiation therapy. Topotecan is a topoisomerase inhibitor indicated for: small cell lung cancer sensitive disease after failure of first-line chemotherapy. ( 1 ) combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and\u002For radiation therapy. ( 1 )",manufacturer:"Accord Healthcare Inc.",splSetId:"7636bc1e-77b6-46ad-9df0-c8bb1c5e503f"}],id:b,nciThesaurus:{casRegistry:"123948-87-8",chebiId:"CHEBI:63632",chemicalFormula:"C23H23N3O5",definition:"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.",fdaUniiCode:"7M7YKX2N15",identifier:"C1413",preferredName:b,semanticType:"Organic Chemical",subclassOf:["C2843"],synonyms:["(s)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione","9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin","Hycamptamine","TOPOTECAN",b,"Topotecan Lactone",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTopotecan",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("topotecan","Topotecan","2021-10-30T13:32:24.083Z")));